End of Year Results is upon us23 Jun 2021 14:19
I posted this somewhere else:
End of year is nearly upon us. What are thoughts/expectations or what good might look like?
My take is somewhere near to £10m revs will be very good, given its still a Covid-ravaged year. Hopefully this half was profitable to help bring down some of the 1.0m loss in H1. AT the very least, I'll be looking for breakeven so we stay static.
I am mindful of this from the H1 Trading Update RNS from Mon 11th Jan where this was statted:
"The Board will also be undertaking an impairment review exercise on certain intangible items on the balance sheet to reflect the impact of Covid-19 and recent trading. This impairment is likely to be substantial but will have no material impact on the Company's prospects, trading outlook or working capital position. The Board expects to conclude this review ahead of the financial year end (30 June 2021)."
I draw particular emphasis on "This impairment is likely to be substantial but will have no material impact on the company's prospects, trading outlook or working capital position". I hope this will mean we will get rid of or write down some of the somewhat dodgy accounting principles that the old lot (read Joe Beyer) was employing by valuing Customer Lists, the valuation applied to ProLong/LifeSciences that clearly is not delivering. If so, this will have a paper-based impact that will likely inflate the loss on paper by a big amount, but I would take that positively as the new team clean up the company.
Key will then be what the company will do to improve in 2021/22 going forward. Its all been very slow to happen and the pace needs to be upped, with visible progress being made in delivering results. Otherwise, I can see a Creightons coming back for another go and this time, it would be difficult resist.